Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (111-120 of 251) with videos related to

Pageof 26
Sort By:
Experimental Hematology|October 11, 2003
Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimenCatherine Faucher, Mohamad Mohty, Norbert Vey, et al.
Bone Marrow Transplantation|September 20, 2019
Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantationCharlotte Nykolyszyn, Angela Granata, Thomas Pagliardini, et al.
American Journal of Hematology|June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalitiesAnne Wanquet, Thomas Prebet, Céline Berthon, et al.
BMC Cancer|October 18, 2008
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genesVéronique Gelsi-Boyer, Virginie Trouplin, José Adélaïde, et al.
Bone Marrow Transplantation|November 8, 2018
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patientsThomas Pagliardini, Samia Harbi, Sabine Fürst, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 25, 2015
Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideJean El-Cheikh, Roberto Crocchiolo, Andrea Vai, et al.
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Genes, Chromosomes & Cancer|April 11, 2012
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasmsMandy Brecqueville, Jérôme Rey, François Bertucci, et al.
Leukemia & Lymphoma|November 22, 2013
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction courseDavid Rizzieri, Norbert Vey, Xavier Thomas, et al.
Oncotarget|April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changesRaynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
Pageof 26

Showing results (111-120 of 251) with videos related to

Sort By:
Pageof 26
Experimental Hematology|October 11, 2003
Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimenCatherine Faucher, Mohamad Mohty, Norbert Vey, et al.
Bone Marrow Transplantation|September 20, 2019
Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantationCharlotte Nykolyszyn, Angela Granata, Thomas Pagliardini, et al.
American Journal of Hematology|June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalitiesAnne Wanquet, Thomas Prebet, Céline Berthon, et al.
BMC Cancer|October 18, 2008
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genesVéronique Gelsi-Boyer, Virginie Trouplin, José Adélaïde, et al.
Bone Marrow Transplantation|November 8, 2018
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patientsThomas Pagliardini, Samia Harbi, Sabine Fürst, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 25, 2015
Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideJean El-Cheikh, Roberto Crocchiolo, Andrea Vai, et al.
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Genes, Chromosomes & Cancer|April 11, 2012
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasmsMandy Brecqueville, Jérôme Rey, François Bertucci, et al.
Leukemia & Lymphoma|November 22, 2013
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction courseDavid Rizzieri, Norbert Vey, Xavier Thomas, et al.
Oncotarget|April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changesRaynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
Pageof 26